ZBIO
Zenas BioPharma, Inc. Common Stock
NASDAQ: ZBIO · HEALTHCARE · BIOTECHNOLOGY
$17.55
-2.55% today
Updated 2026-04-29
Market cap
$1.09B
P/E ratio
—
P/S ratio
109.46x
EPS (TTM)
$-8.44
Dividend yield
—
52W range
$9 – $45
Volume
0.7M
Zenas BioPharma, Inc. Common Stock (ZBIO) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 7
Last 7 quarters
Avg EPS surprise
-59.8%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
-260.3%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+3.7%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+12.1%
2025-08-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-16 | $-4.54 | -281.5% | $24.04 | $23.48 | -2.3% |
| 2025-11-12 | $-1.22 | -43.5% | $35.20 | $35.66 | +1.3% |
| 2025-08-12 | $-1.25 | -17.9% | $14.91 | $16.71 | +12.1% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-1.19 | $-4.54 | -281.5% | — | — |
| 2025-09-30 | $-0.85 | $-1.22 | -43.5% | — | — |
| 2025-06-30 | $-1.06 | $-1.25 | -17.9% | — | — |
| 2025-03-31 | $-1.03 | $-0.80 | +22.3% | $10.00M | — |
| 2024-12-31 | $-1.02 | $-1.26 | -23.7% | $5.00M | — |
| 2024-09-30 | $-9.30 | $-5.02 | +46.0% | — | — |
| 2024-06-30 | $-1.24 | $-2.79 | -125.0% | — | — |
Frequently asked questions
Has Zenas BioPharma, Inc. Common Stock beaten earnings estimates?
Zenas BioPharma, Inc. Common Stock has beaten Wall Street EPS estimates in 2 of its last 7 quarterly reports, with an average EPS surprise of -59.8% over the last 4 quarters.
How does ZBIO stock react to earnings?
ZBIO stock has moved an average of +3.7% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.